Abiprubart not checked
Kiniksa Pharmaceuticals, Ltd. · KPL-404
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- Tested for
- Arthritis, Rheumatoid, Sjögrens Disease
- Main trialPhase 2
- “Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.”In the company’s words, NCT05198310 on ClinicalTrials.gov
- Other names
- KPL-404
Other drugs for Arthritis, Rheumatoid
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 8 Feb 2024 | Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor | |
| Phase 2Terminated | 6 Mar 2025 | A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease | |
| Phase 1Completed | 21 Jan 2021 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026